Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The University of Texas Health Science Center at San Antonio
This study will evaluate change from baseline in gamma-delta T cell numbers and function and Ag85 peptide-specific T cell responses following treatment.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologically (histologically) proven diagnosis of non-muscle invasive (Ta, Tis or T1) bladder cancer
In their treating physician's opinion is a good candidate for BCG therapy
Be able to give informed consent
Be age 18 or older
Not be in an immunosuppressed state (e.g. HIV, use of chronic steroids)
Not have active, uncontrolled infections
Not be on agents known to alter rapamycin metabolism significantly
Not have a reported history of liver disease (e.g. cirrhosis)
Not have a prior history of non-bladder cancer unless the cancer is clinically stable and not requiring active treatment except basal cell carcinoma or squamous cell carcinoma of the skin.
Not pregnant, or taking effective contraception before rapamycin therapy, during therapy and for 12 weeks after discontinuation of therapy.
You may not be if
Have muscle-invasive (≥T2) bladder cancer
Unable to give informed consent
Age \< 18
Immunosuppressed state (e.g. HIV, use of chronic steroids)
Active, uncontrolled infections
On agents known to alter rapamycin metabolism significantly
Another cancer requiring active treatment (except basal cell carcinoma or squamous cell carcinoma of the skin)
Patients at risk of pregnancy who are unwilling or unable to take effective contraception before rapamycin therapy, during therapy, and for 12 weeks after discontinuation of therapy.
Individuals with a reported history of liver disease (e.g. cirrhosis)
Individuals who are not a good candidate for BCG in their treating physician's opinion
